Literature DB >> 7735297

Pituitary adenylate cyclase activating peptide-38 (PACAP-38), PACAP-27, and PACAP related peptide (PRP) in the rat median eminence and pituitary.

J D Mikkelsen1, J Hannibal, J Fahrenkrug, P J Larsen, J Olcese, C McArdle.   

Abstract

Pituitary adenylate cyclase activating peptide (PACAP) is a member of the vasoactive intestinal peptide-like peptide family. It is found in the hypothalamus, where the PACAP precursor is processed to form PACAP-38, the C-terminal truncated PACAP-27 and PACAP related peptide (PRP). Both PACAPs are potent stimulators of anterior pituitary adenylate cyclase activity, but the physiologically relevant anatomical sources of PACAP and possible importance of PRP in this regard are poorly understood. Using immunocytochemistry with epitope-specific antisera, we now show that PACAP38-, PACAP27- and PRP-positive nerve fibres are all present in the rat median eminence. The major immunoreactive species present was PACAP38. Numerous PACAP38-immunoreactive nerve fibres were observed in the internal layer and a few were present in the posterior pituitary lobe. The external layer of the median eminence contained a few PACAP-38-immunoreactive fibres and PACAP-38-positive nerve terminals were rarely seen in the perivascular portal spaces. Surprisingly, delicate PACAP-38-positive nerve fibres were identified in the anterior pituitary lobe intermingled between the pituitary cells although none of the secretory pituitary cells contained immunoreactive PACAP38, PACAP27 or PRP and preproPACAP mRNA was not detected in the gland by Northern blotting or in situ hybridization. PACAP-27- and PRP-immunoreactive nerve fibres and terminals were found in the same locations as PACAP-38 although generally in lower numbers. Specific radioimmunoassays and HPLC revealed that PACAP-38 accounts for the vast majority of the adenohypophyseal PACAP-immunoreactivity, whereas PACAP-27 and PRP were found in low to undetectable concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7735297     DOI: 10.1111/j.1365-2826.1995.tb00666.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  11 in total

1.  Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP.

Authors:  Henrik Winther Schytz; Helle Holst; Lars Arendt-Nielsen; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2010-05-09       Impact factor: 7.277

Review 2.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

3.  Identification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin.

Authors:  J W Tams; A H Johnsen; J Fahrenkrug
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

Review 4.  PACAP: A regulator of mammalian reproductive function.

Authors:  Stephen J Winters; Joseph P Moore
Journal:  Mol Cell Endocrinol       Date:  2020-06-17       Impact factor: 4.102

Review 5.  Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Authors:  Anne Luise Haulund Vollesen; Faisal Mohammad Amin; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

6.  PACAP protects against TNFα-induced cell death in olfactory epithelium and olfactory placodal cell lines.

Authors:  Shami Kanekar; Mahendra Gandham; Mary T Lucero
Journal:  Mol Cell Neurosci       Date:  2010-07-21       Impact factor: 4.314

7.  Pituitary adenylate cyclase-activating peptide (PACAP) in the retinohypothalamic tract: a potential daytime regulator of the biological clock.

Authors:  J Hannibal; J M Ding; D Chen; J Fahrenkrug; P J Larsen; M U Gillette; J D Mikkelsen
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

8.  High-resolution characterization of a PACAP-EGFP transgenic mouse model for mapping PACAP-expressing neurons.

Authors:  Michael C Condro; Anna Matynia; Nicholas N Foster; Yukio Ago; Abha K Rajbhandari; Christina Van; Bhavaani Jayaram; Sachin Parikh; Anna L Diep; Eileen Nguyen; Victor May; Hong-Wei Dong; James A Waschek
Journal:  J Comp Neurol       Date:  2016-06-03       Impact factor: 3.215

9.  Weaning and the developmental changes in follicle-stimulating hormone, pituitary adenylate cyclase-activating polypeptide, and inhibin B in the male rat.

Authors:  Joseph P Moore; Stephen J Winters
Journal:  Biol Reprod       Date:  2007-12-26       Impact factor: 4.285

10.  Pituitary adenylate cyclase-activating polypeptide does not colocalize with vasoactive intestinal polypeptide in the hypothalamic magnocellular nuclei and posterior pituitary of cats and rats.

Authors:  Viktoria Vereczki; Katalin Köves; Zsuzsanna E Tóth; Akemichi Baba; Hitoshi Hashimoto; Kristóf Fógel; Akira Arimura; Mária Kausz
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.